Hence then, the article about phase 2 data for erleada apalutamide plus androgen deprivation therapy following radical prostatectomy in patients with high risk localized prostate cancer show 100 biochemical free recurrence rate more than two years post surgery was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery )
Also on site :
- Pardoned Jan 6 rioter chased from pro-ICE rally in Minneapolis after blasting ‘Ice, Ice Baby’ and threats to burn Quran
- Russia-Ukraine war: List of key events, day 1,424
- Blake Shelton Issues Bold Response to a Viral Month-Long Trend: ‘It’s Freaking Me Out’